SCHEMBL5653059

SCHEMBL5653059

COc1ccccc1CCOCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.59
TAAR1 Q96RJ0 1/20 0.53
KCNH2 Q12809 1/20 0.51
BCHE P06276 5/20 0.51
ABCG2 Q9UNQ0 2/20 0.50
HTR1A P08908 2/20 0.50
DRD2 P14416 2/20 0.50
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
NPY1R P25929 1/20 0.49
HTT P42858 1/20 0.49
NPY2R P49146 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SIGMAR1 Q99720 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
IDO1 P14902 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9190330 0.85 TAAR1 (0.64) ABCB1TAAR1KCNH2BCHESIGMAR1
SCHEMBL7591220 0.84 HTR1A (0.71) ABCB1ABCG2HTR1ADRD2KDM4E
SCHEMBL5436452 0.82 ABCB1 (0.49) ABCB1TAAR1BCHEABCG2HTR1A
SCHEMBL8372624 0.81 ABCB1 (0.47) ABCB1TAAR1BCHEHTR1AKDM4E
SCHEMBL11419575 0.80 ABCB1 (0.60) ABCB1KCNH2BCHEABCG2SIGMAR1
SCHEMBL7335269 0.80 ABCB1 (0.80) ABCB1TAAR1KCNH2ABCG2HTR1A
SCHEMBL15899172 0.79 HTR1A (0.46) ABCB1HTR1ADRD2LMNAHTT
SCHEMBL15899170 0.79 HTR1A (0.46) ABCB1HTR1ADRD2LMNAHTT
SCHEMBL987104 0.79 ABCB1 (0.57) ABCB1BCHEABCG2TDP1L3MBTL1
SCHEMBL792023 0.77 TAAR1 (0.64) ABCB1TAAR1KCNH2HTTSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250432-B2 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-31 US disclosed
WO-2006126751-A1 NEW DIARYL-ISOXAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME FOR THE PREVENTION AND THE TREATMENT OF CANCERS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2006-11-30 WO disclosed
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers UACA, SQLE, ALDH1A2 ABCB1 309/4885TAAR1 4788/4885KCNH2 3261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.